Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 88 of 97, showing 5 Applications out of 482 total, starting on record 436, ending on 440

# Protocol No Study Title Investigator(s) & Site(s)

436.

ECCT/13/07/04   Advanced Kapsosis Sarcoma Chemotherapy Regimens
    A Randomized Comparison of Three Regimens of Chemotherapy with Compatible Antiretroviral Therapy for Treatment of Advanced AIDS-KS in Resource-Limited Settings   
Principal Investigator(s)
1. Josphat Kosgei
Site(s) in Kenya
1. WRP/KEMRI - Kericho (Kericho county)
2. AMPATH - MOI University Teaching Hospital Eldoret CRS (Uasin Gishu county)
 
View

437.

ECCT/10/11/06   Randomized Comparison of ART Alone versus ART with Immediate Chemotherapy
    A5264/AMC 067 "A Randomized Evaluation of Antiretroviral Therapy Alone or with Delayed Chemotherapy versus Antiretroviral Therapy with Immediate Adjunctive Chemotherapy for Treatment of Li1mited Stage AIDS-KS in Resource-Limited Settings (REACT-KS)"   
Principal Investigator(s)
1. Abraham Mosigisi Siika
Site(s) in Kenya
1. Walter Reed Project Kericho (Kericho county)
2. Moi University Clinical Research Centre (Uasin Gishu county)
 
View

438.

ECCT/13/07/03  
    Pharmacokinetic and pharmacodynamic studies of efficacy, tolerability and safety of higher dosage rifapentine for treatment of tuberculosis   
Principal Investigator(s)
1. Dr Lena Matata
Site(s) in Kenya
KEMRI-CDC
 
View

439.

ECCT/13/08/01   M72/AS01 E
    A phase IIb, double-blind, randomised, placebo-controlled study to evaluate the efficacy, safety and immunogenicity of GSK Biologicals’ candidatetuberculosis (TB) vaccine GSK 692342 against TB disease, in healthy adults aged 18-50 years, living  in a TB endemic region.   
Principal Investigator(s)
1. Dr Videlis Nduba
Site(s) in Kenya
KEMRI-CDC
 
View

440.

ECCT/12/07/01   MULTI-OCTAVE (Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure)
    A5288 "Management Using the Latest Technologies in Resource-limited Settings to Optimize Combination Therapy After Viral Failure" (MULTI-OCTAVE)   
Principal Investigator(s)
1. Abraham Mosigisi Siika
Site(s) in Kenya
Moi University Clinical Research Centre
 
View